This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.
The aim of this study was to explore the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in patients with solid tumors or lymphoma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.
The First Hospital of China Medical University
Shenyang, Liaoning, China
Incidence of 68Ga-NODAGA-SNA006-emergent Adverse Events
Through PET/CT, Visual analysis was positive, or the SUVmax was more than the mediastinum
Time frame: 3 YEAR
Biodistribution of 68Ga-NODAGA-SNA006
Through PET/CT analysis, SUVmax and SUVmean of the organs
Time frame: 3 YEAR
Correlation analysis of 68Ga-NODAGA-SNA006 uptake and tumor immune phenotype
Correlation coefficients (r²) between SUVmax and SUVmean measured by PET/CT and immunophenotypes
Time frame: 3 YEAR
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.